Similarly, pathway enrichment results revealed a marked involvement in the JAK–STAT, interferon, and mTOR signaling pathways, suggesting that MTAP/CDKN2AMUT may activate the anti-tumor immune response in the TME of RCC (Figure 5B). The gene discussed is MTAP; the disease is renal cell carcinoma.